Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

1. EGFR T790M mutation alone or exon 20 insertions as unique mutation

2. Tumors with a squamous component

3. Prior chemotherapy or any other medical treatment for advanced NSCLC (previous neoadjuvant or adjuvant chemotherapy is allowed if \> 6 months before randomisation)

4. Radiotherapy to any site for any reason within 28 days prior to randomization (palliative radiotherapy to bone lesions is allowed if ≥ 14 days before randomization)

5. Full-dose anticoagulation with warfarin

6. Current or recent (within 10 days of enrolment) use of aspirin (\>325 mg/day) or chronic use of other full-dose nonsteroidal anti-inflammatory drugs (NSAIDs) with anti-platelet activity

7. Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450 3A4 (CYP3A4) are prohibited =\< 7 days prior to registration

8. Receiving any medications or substances that are inducers of CYP3A4 use of inducers are prohibited =\< 7 days prior to registration

9. Inadequate coagulation parameters:

* activated partial thromboplastin time (APTT) \>1.5 x the upper limit of normal (ULN) or

* INR \>1.5

10. Inadequate liver function, defined as:

* serum (total) bilirubin \>1.5 x ULN

* AST/SGOT or ALT/SGPT \>2.5 x ULN

11. Inadequate renal function, defined as:

* serum creatinine \>2.0 mg/dl or \>177 micromol/l

* urine dipstick for proteinuria \>2+. Patients with \> o = 1+ proteinuria at baseline dipstick analysis must undergo a 24-hour urine collection and must demonstrate ≤1g of protein in their 24-hour urine collection.

12. Pregnancy or breast-feeding

13. Inadequately controlled hypertension (defined as systolic blood pressure \>150 and/or diastolic blood pressure \>100 mmHg on antihypertensive medications)

14. History of gross hemoptysis within 3 months prior to randomization unless definitively treated with surgery or radiation

15. History of any of the following within 6 months prior to randomisation: serious systemic disease, unstable angina, New York Heart Association (NYHA) Grade 2 or greater Congestive Heart Failure (CHF), unstable symptomatic arrhythmia requiring medication, clinically significant peripheral vascular disease, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess

16. Serious, non-healing wound, ulcer, or bone fracture

17. Evidence of bleeding diathesis or coagulopathy or other serious or acute internal bleeding within 6 months prior to randomization

18. Central Nervous System (CNS) bleeding; history or clinical evidence of CNS stroke (hemorrhagic or thrombotic) within the last 6 months

19. In-patient surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization

20. Minor surgical procedure, fine needle aspirations or core biopsy within 7 days prior to randomization

21. Anticipation of need for a major surgical procedure during the course of the study

22. Inability to take oral medication or requirement for intravenous (IV) alimentation or total parenteral nutrition with lipids, or prior surgical procedures affecting absorption

23. Evidence of confusion or disorientation, or history of major psychiatric illness that may impair the patient's understanding of the Informed Consent Form or his/her ability to comply with study requirements

24. Any other invasive malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically resected prostate cancer with normal PSA)

25. Brain metastasis

26. Patients who have had radiotherapy ≥ 4 weeks prior to the first dose of study treatment, but who are still experiencing acute toxic effects of radiotherapy

27. Known HIV positive patients (patients with both acute or chronic infection are excluded)

28. Active HBV or HCV infection (patients with chronic non-active infection are eligible)

29. Any already known inflammatory changes of the surface of the eye at baseline

30. Any other concomitant pathologies or laboratory alterations that prevent or contraindicate the use of erlotinib or bevacizumab.

What this study is about